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ABSTRACT 
Background: Myocardial infarction (MI) is an ischemic wound that recruits millions of 
leukocytes. MI-associated blood leukocytosis correlates inversely with patient survival, yet the 
signals driving heightened leukocyte production after MI remain incompletely understood. 
Methods and Results: Using parabiosis surgery, this study shows that soluble danger signals, 
among them interleukin-1 beta (IL-1β), increase bone marrow hematopoietic stem cell (HSC) 
proliferation after MI. Data obtained in bone marrow reconstitution experiments reveal that IL-1β 
enhances HSC proliferation by both direct actions on hematopoietic cells and through 
modulating the bone marrow’s hematopoietic microenvironment. An antibody that neutralizes IL-
1β suppresses these effects. Anti-IL-1β treatment dampens the post-MI increase in HSC 
proliferation. Consequently decreased leukocyte numbers in the blood and infarct reduce 
inflammation and diminish post-MI heart failure in ApoE-/- mice with atherosclerosis.  
Conclusion: The presented insight into post-MI bone marrow activation identifies a mechanistic 
target for muting inflammation in the ischemically damaged heart. 
 
 
 
Key words: myocardial infarction, bone marrow hematopoiesis, hematopoietic stem cells, 
interleukin-1β
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Myocardial infarction (MI) inflicts a sterile cardiac wound that, within minutes, recruits leukocytes 
from circulation at a rate of several hundred thousand cells per day. This demand depletes 
blood pool leukocytes quickly and requires continuous resupply over the next several days. In 
mice, the spleen initially serves as a leukocyte reservoir1 contributing ~50% of myeloid cells to 
the infarct in the early hours after coronary ligation. Thereafter, emergency hematopoiesis fuels 
the increased demand for myeloid cells2-4. Sympathetic nervous system activity triggers 
hematopoietic progenitor migration to the spleen, initiating extramedullary myelopoiesis3. 
 
The mechanisms of increased hematopoietic system activity after ischemic injury are 
incompletely understood5. The sympathetic nervous system activates the bone marrow after MI3 
and in mice exposed to chronic psychosocial stress6. This activation increases hematopoietic 
stem and progenitor cell (HSPC) proliferation and migration via chemokine C-X-C motif ligand 
12 (CXCL12) / C-X-C chemokine receptor type 4 (CXCR4) signaling7. Soluble factors released 
from ischemic myocardium into the blood may also signal to the bone marrow to drive 
hematopoietic stem cells (HSC) proliferation remotely. These post-MI stimuli could act on either 
HSC directly or niche cells that regulate the bone marrow microenvironment. Data obtained 
from mice with infection or injected systemic stimuli suggest that circulating danger signals may 
activate hematopoiesis8, 9. 
 
The pro-inflammatory cytokine interleukin-1 beta (IL-1β) may provide one such hematopoiesis 
activation signal. Increased bone marrow progenitor proliferation after injection of the chemical 
compound alum, which is used as a vaccination adjuvant, was attenuated in IL-1 receptor 
deficient mice10. IL-1β also stimulates myelopoiesis in obesity11. IL-1β is first synthesized as its 
cytosolic precursor pro-IL-1β and then gives rise to its active form via caspase-1, an enzyme in 
turn regulated by the NLRP3 inflammasome12, 13. IL-1β and IL-1α both signal using the receptor 
IL-1R114, 15. IL-1R2, the other IL-1 receptor, functions as a decoy for IL-116, 17. Further, IL-1β 
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instigates inflammation in atherosclerotic plaque18 and ischemic myocardium13. IL-1β rises in 
patient serum after acute MI19, and both preclinical and clinical pilot data suggest anti-IL-1 
therapy can provide benefit after MI20-22 and in atherosclerosis23-25.  
 
This study shows that after MI, soluble factors that reach the bone marrow via the circulation 
significantly accelerate hematopoiesis. Parabiosis experiments revealed that IL-1β stimulates 
systemic leukocyte production by a) directly acting on hematopoietic stem cells and b) 
modulating the stem cell microenvironment in the bone marrow. Administration of an anti-mouse 
IL-1β reduced post-MI emergency hematopoiesis and attenuated leukocytosis. In ApoE-/- mice 
with atherosclerosis, anti-IL-1β therapy moderated leukocyte overproduction, supported 
resolution of infarct inflammation and ameliorated post-MI heart failure. 
 
 
METHODS 
A detailed methods description is provided in the online supplement. 
Experimental animals. We used female C57BL/6J (WT, n = 162), B6.129S7-Il1r1tm1Imx/J 
(IL1R1-/-, n = 28) and apolipoprotein E–deficient (ApoE-/-; B6.129P2-Apoetm1Unc/J, n = 24) 
mice aged 8-12 weeks (The Jackson Laboratories, Bar Harbor, ME, USA) for our studies. We 
also used transgenic mice expressing green fluorescent protein (GFP) under the Nestin-
promoter (Nestin-GFP, n = 10)26, 27. Nestin-GFP mice were a gift from Dr. Grigori Enikolopov 
(Cold Spring Harbor Laboratory, NY, USA). Age-matched mice were randomly allocated either 
to control or treatment groups. The study was approved by the Subcommittee on Animal 
Research Care at Massachusetts General Hospital (Boston, MA). 
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Myocardial infarction surgery. Myocardial infarction was induced by permanent ligation of the 
left anterior descending coronary artery as described previously3. Ischemia Reperfusion Injury 
was induced and assessed as described previously28. Please also see the online supplement. 
 
Neutralizing IL-1β. The IL-1β neutralizing antibody was a donation from Novartis (Basel, 
Switzerland). The antibody selectively binds IL-1β, thus blocking the interaction of the cytokine 
with its receptors. We used a monoclonal, mouse anti-mouse IL-1β IgG2a/k antibody derived 
from an IgG1/k antibody as described by Geiger et al.29. The in vitro potency IC50 is about 25 
pM, and its affinity to murine IL-1β is about 300 pM. The t1/2 in mice is 14 days30. We initiated 
treatment 2 h after induction of MI with subcutaneously injecting 10 mg/kg bodyweight of the IL-
1β antibody (or a mouse monoclonal IgG2a antibody raised against cyclosporine A as isotype 
control). We repeated injections once weekly over the study period. 
 
BrdU experiments. To assess proliferation, we used FITC/APC BrdU (bromodeoxyuridine) flow 
kits (BD Bioscience). For these BrdU pulse experiments, one mg BrdU was injected 
intraperitoneally 24h prior to euthanization and subsequent organ harvest. After surface 
staining, intracellular BrdU staining was performed according to the manufacturer’s protocol. 
Flow cytometry and cell sorting procedures are described in the online supplement. 
 
Bone marrow reconstitution. We lethally irradiated WT or IL1R1-/- mice with 950 cGy. We then 
reconstituted mice with 2x106 whole bone marrow cells from either WT or IL1R1-/- mice. Two to 
four months later mice received coronary ligation. Please also see the online supplement. 
 
Administration of recombinant mouse IL-1β. We injected 2.5 µg of recombinant mouse IL-1β 
(R&D Systems, MN, USA) i.p. daily over two days as described elsewhere31 and then harvested 
the bone marrow 48h after the first administration. 
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Statistics. Statistical analyses were carried out using GraphPad Prism software version 6 
(GraphPad Software, Inc.). Results are displayed as mean ± standard deviation (SD). First, 
values were tested for Gaussian distribution (D'Agostino-Pearson omnibus normality test). For 
two-group comparisons, an unpaired t-test was applied to normally distributed variables, a 
Mann-Whitney test to non-normally distributed variables. For comparing more than two groups, 
a one-way ANOVA test, followed by a Sidak’s test for multiple comparisons, was applied. P 
values of < 0.05 indicated statistical significance. 
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RESULTS 
IL-1β released after MI activates bone marrow hematopoiesis 
It is unclear how the hematopoietic system, which responds to acute myocardial ischemia with 
increased proliferation, receives signals to increase leukocyte production. We asked whether 
HSC activation relies on a circulating factor, released after MI, that reaches the bone marrow via 
the blood. To test this hypothesis, we joined the circulation of two wild type mice in parabiosis. 
After 2 weeks, a period necessary to establish shared circulation, one parabiont underwent 
coronary ligation while the other did not. Two days later, we assessed HSC proliferation in the 
bone marrow of the non-infarcted parabiont by BrdU incorporation (Fig. 1a). Lin- Sca-1+ c-Kit+ 
CD48- CD150+ HSC proliferation in non-infarcted parabionts increased significantly (Fig. 1a), 
indicating that factor(s) circulating in blood contribute to hematopoietic activation after MI. In 
humans, IL-1β levels rise in the blood after MI19. Accordingly, we found IL-1β mRNA and protein 
levels increased in the infarcted heart (Fig. 1b), in circulation and in the bone marrow (Fig. 1c.) 
These data indicate this cytokine transfers signals from the site of ischemic injury to the 
hematopoietic system. Injecting recombinant mouse IL-1β (rmIL-1β) into naive mice triggered 
HSC proliferation similar to that observed after MI (Fig. 1d). We next joined wild type and 
interleukin-1 receptor 1 knockout mice (IL1R1-/-) in parabiosis. Two days after coronary artery 
ligation in one parabiont, increased HSC proliferation observed in the non-ischemic wild type 
parabionts significantly diminished in IL1R1-/- mice (Fig. 1a). Taken together, these data indicate 
that IL-1β crossed from the circulation of the infarcted parabiont to that of the non-infarcted 
parabiont and instigated increased HSC proliferation in the bone marrow. 
 
IL-1β effector cells 
Bone marrow stromal cells form a microenvironment that harbors hematopoietic stem and 
progenitor cells (HSPC)7. These niche cells maintain hematopoiesis by producing factors that 
signal to HSPC and regulate their dormancy, retention and lineage bias. Therefore, our next 
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question addressed how IL-1β stimulates HSC proliferation: does IL-1β affect hematopoietic 
cells directly or act on niche cells regulating HSC activity? To address this issue, we 
investigated which bone marrow cells can sense IL-1β. Using qRT-PCR in FACS-isolated bone 
marrow cells (for gating; please see Fig. 2a), we found that HSC, Lin- Sca-1+ c-Kit+ (LSK), as 
well as all stromal cells regulating HSPC activity, including mesenchymal stromal cells, 
endothelial cells and osteoblasts, express the interleukin-1 receptor 1 (Fig. 2a), with higher 
expression in the non-hematopoietic niche cells. We then reconstituted lethally irradiated wild 
type mice with whole bone marrow from either wild type (recipients’ bone marrow HSC and 
bone marrow stromal cells are IL1R1+/+) or from IL1R1-/- mice (recipients’ bone marrow HSC 
lack IL1R1 while the bone marrow stromal cell are IL1R1 competent). Four months later, mice 
underwent coronary ligation. Subsequent analysis showed significantly decreased HSC 
proliferation in mice reconstituted with IL1R1-/- bone marrow (Fig. 2b). In these mice, in which 
hematopoietic but not niche cells were unresponsive to IL-1β, BrdU incorporation in HSC was 
still markedly above chimeras without MI (Fig. 2b). The data indicate that IL-1β's hematopoietic 
effect involves direct as well as indirect action on hematopoietic cells. To compare IL-1β effects 
on HSC with indirect effects on hematopoiesis via niche cells, we transplanted wild type bone 
marrow into lethally irradiated IL1R1-/- recipients (Suppl. Fig. 1a). In this scenario, bone marrow 
hematopoietic cells are responsive to IL-1β while the marrow’s stromal cells are not. In a second 
group, lethally irradiated WT mice received IL1R1-/- bone marrow, resulting in the opposite 
situation. We then investigated the relevance of these two scenarios for post MI recovery 
(Suppl. Fig. 1b and c). Cardiac function by MRI was similar in both groups 21 days after 
coronary ligation, and blood leukocyte numbers were also comparable (Suppl. Fig. 1d-1f) 
indicating that IL-1β’s direct action on HSPC and indirect action via stromal cells are equally 
important for the post MI increase in leukocyte production. 
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Neutralizing IL-1β reduces post-MI bone marrow HSPC proliferation and leukocytosis 
Thus far, these data show IL-1β involvement in triggering post-MI emergency hematopoiesis. 
This activated heart-bone marrow axis may represent a therapeutic target for reducing 
leukocyte overproduction after MI, a process that may lead to heart failure and secondary 
ischemic events5. To test how IL-1β neutralization changes leukocyte production, we chose the 
clinically relevant murine version of canakinumab. Treatment began two hours after coronary 
ligation, and we assessed bone marrow HSPC proliferation by measuring BrdU incorporation 48 
hours later. HSC and LSK proliferation were markedly lower in treated mice compared to a 
control IgG treated cohort that also underwent coronary artery ligation (Fig. 3a). The treatment 
effects were somewhat lower than the decrease in HSC proliferation observed in IL-1R-/- mice, 
possibly because IL-1R1-/- mice lack both, IL-1α as well as the IL-1β signaling. Nevertheless, 
antibody treatment significantly reduced frequencies of HSC and LSK in the active S+G2/M 
phase of the cell cycle, as determined by Ki67 and DAPI staining for cell cycle analysis (Fig. 
3b). A third method of measuring hematopoietic progenitor proliferation detected a lower 
number of colony forming units derived from the bone marrow of treated mice (Fig. 3c). 
Reduced hematopoietic progenitor activity led to fewer circulating neutrophils on day 3 and 
decreased neutrophil and Ly6Chigh monocyte levels on day 7 after MI (Suppl. Fig. 2a and Fig. 
3d). 
 
Neutralizing IL-1β reduces extramedullary hematopoiesis 
The bone marrow chimera data indicate that IL-1β may act on bone marrow niche cells. Indeed, 
anti-IL-1β treatment preserved mRNA levels of VCAM-1, angiopoietin-1 and osteopontin after 
coronary ligation (Fig. 4a). Cell-specific treatment effects are shown in Suppl. Fig. 3. These 
effects likely contributed to the treatment-induced decrease in myeloid cell production, as 
angiopoietin-1, osteopontin and CXCL12 regulate hematopoietic progenitor quiescence32, 33. 
VCAM-1 retains HSPC in the hematopoietic niche. When VCAM-1 expression falls after MI, 
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HSPC release into circulation and seed the spleen3. Indeed, HSPC release from the bone 
marrow into the blood decreased in mice treated with the anti-IL-1β antibody (Fig. 4b). 
Consequently, spleens of mice treated with anti-IL-1β antibody contained fewer LSK and GMP 
(granulocyte-macrophage progenitors) than controls (Fig. 4c). 
 
Neutralizing IL-1β reduces inflammation in myocardial infarcts 
Leukocytes mobilize rapidly to the infarct after onset of ischemia, and, due to their fast turnover, 
the extent of their accumulation depends on their supply from the circulation5, 34. We 
consequently tested whether lowering blood leukocyte numbers in the anti-IL-1β treatment 
group would reduce leukocyte recruitment to the ischemic heart. Indeed, we detected fewer 
recruited myeloid cells on day 3 and 7 after coronary ligation by flow cytometry and 
immunohistochemistry (Fig. 5 and Suppl. Fig. 2b). These data corroborate previous reports by 
the Frangogiannis group35, 36. 
 
Therapeutically targeting IL-1β signaling improves infarct healing and reduces post-MI 
remodeling 
We next evaluated the impact of antibody-mediated IL-1β signaling blockade on infarct healing 
and post-MI heart failure in ApoE-/- mice on high-fat diet. We chose to study dyslipidemic mice 
because they mimic two aspects of clinical myocardial infarction: an atherogenic milieu and 
chronically activated innate immunity37. Even without MI ApoE-/- mice have augmented 
myelopoiesis due to increased progenitor cycling in the bone marrow38 and the spleen39. In a 
serial imaging trial, delayed enhancement MRI determined comparable infarct size in both 
cohorts on day 1 after permanent occlusion of the coronary artery (Fig. 6a). In a separate 
cohort, anti-IL-1β treatment did not change ischemia reperfusion injury (Suppl. Fig. 4). On day 7 
after MI, mice underwent FMT/CT imaging to determine infarct protease activity with a 
molecular imaging agent (pan-cathepsin reporter)40. At this time point, this molecular imaging 
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signal reports on the resolution of cardiac inflammation. FMT/CT revealed that anti-IL-1β 
treatment significantly reduced protease activity in the infarct (Fig. 6b) which we located using 
the hybrid CT modality. Mice were then re-imaged by MRI 3 weeks after MI. In comparison to 
controls, anti-IL-1β treated ApoE-/- mice exhibited smaller end-diastolic volumes and a better 
preservation of the left ventricular ejection fraction (Fig. 6c). Histological analysis of wound 
healing biomarkers in a cohort of WT mice sacrificed on day 7 after coronary ligation showed 
that anti-IL-1β treatment reduced staining for the myofibroblast marker α smooth muscle actin 
(αSMA) and collagen-1, while the density of sprouting capillaries in the granulation tissue did 
not change (Fig. 7a). In accord with the histological data, TGF-β1 and MMP-3 mRNA fell and 
TIMP-1  and TIMP-2 mRNA increased in the infarct and borderzone of the treatment group 7 
days after coronary ligation (Fig. 7b). In addition, mRNA levels for the pro-inflammatory genes 
tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) fell, concordant with the observed 
reduction of inflammatory myeloid cells at this time point. 
 
Anti-IL-1β treatment reduces adhesion molecule expression and shifts macrophage 
phenotype 
To explore how local mechanisms may contribute to the observed salient effects of anti-IL-1β 
treatment, we examined the mRNA levels of adhesion molecules in infarct tissue. IL-1β 
neutralization reduced ICAM-2 and P-selectin expression, while ICAM-1, VCAM-1 and E-
selectin expression were unchanged on day 7 after coronary artery ligation (Fig. 8a), indicating 
that reduced IL-1β signaling dampens leukocyte recruitment. We also investigated how IL-1β 
influences the infarct macrophage phenotype. We isolated CD45high CD11bhigh F4/80high 
macrophages by flow sorting from 4 day old infarcts and measured mRNA levels of several 
M1/M2 macrophage markers (Fig. 8b). Anti-IL-1β treatment shifted macrophage polarization 
away from the inflammatory M1 phenotype, indicating that anti-IL-1β therapy augments 
resolution of inflammation in acute infarcts. 
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DISCUSSION 
Recent experiments link atherosclerosis and MI, its dreaded clinical complication, with bone 
marrow activation5. Yet whether soluble systemic factors mediate this crosstalk between organs 
remained unknown. This study provides evidence that circulating, blood-borne factors contribute 
to bone marrow activation during MI. After joining the circulation of two mice in parabiosis, one 
mouse underwent coronary ligation. The observed increase in HSC proliferation in the bone 
marrow of the non-infarcted parabiont must result from signaling by soluble mediators that 
crossed from the circulation of the infarcted mouse to the non-infarcted mouse. Here we report 
that IL-1β participates in the process and contributes to bone marrow activation after MI via 
direct effects on hematopoietic cells and indirect effects that modulate the hematopoietic bone 
marrow microenvironment. Finally, we found that neutralizing IL-1β with the murine version of 
an antibody currently under investigation in a large-scale human trial41 can limit bone marrow 
activation. Anti-IL-1β treatment lowered the post-MI increase in HSC proliferation, reducing 
leukocytes in the blood and ischemic heart. Inhibiting this driver of inflammation favored infarct 
healing and attenuated left ventricular remodeling in mice with atherosclerosis, a harbinger of 
the development of heart failure post MI, as in previous reports on non-atherosclerosis-prone 
mice35, 42. 
 
Although the bone marrow generates billions of cells every day, leukocyte numbers in the 
steady state follow circadian rhythms within tightly regulated boundaries. Only a minor fraction 
of HSC actively cycle, while the niche cells forming the hematopoietic microenvironment use 
signals such as CXCL12 to keep stem cells quiescent7. In response to infection and other 
stressors, a variety of signals, including interferons and Toll-like receptor ligands, increase 
leukocyte output to meet the heightened demand for these innate immune cells during host 
defense against invading pathogens. These danger signals may act directly on hematopoietic 
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stem cells that express receptors to sense danger-associated molecular patterns. Alternatively, 
alarmins may modulate the activity of niche cells, including endothelial cells and mesenchymal 
stromal cells, among others7, 43. In the setting of cardiovascular disease, blood leukocytosis 
correlates with mortality5; however, the signals that increase leukocyte production are 
incompletely understood. In mice with atherosclerosis, insufficient cholesterol efflux from cells 
may induce increased HSPC cycling in the bone marrow38 and spleen39, thereby leading to 
hyperlipidemia-associated monocytosis44, heightening macrophage recruitment into the vessel 
wall and progressing inflammation in the plaque. In this regard, a high macrophage burden 
characterizes plaques that have given rise to MI in humans45. 
 
During MI, increased sympathetic nervous system activity may trigger an additional burst of 
hematopoiesis by reducing bone marrow levels of CXCL12 and SCF, important HSC retention 
factors that induce quiescence3. We hypothesized that circulating factors also contribute to 
activating hematopoiesis, as seen after infection or other systemic injury. We specifically tested 
IL-1β because previous studies have implicated this cytokine in regulating hematopoiesis after 
injection of the chemical compound alum10 and because IL-1β levels increase after myocardial 
infarction in rats46 and humans19. Our data indicate that post-MI, IL-1β signaling in the bone 
marrow acts through two mechanisms: IL-1β directly binds IL-1R1 expressed by HSC and 
indirectly affects leukocyte production through signaling to the niche cell compartment. In this 
microenvironment, antagonizing IL-1β preserved several HSC retention factors and inhibited the 
HSC and LSK release after MI, reducing their migration to the spleen and attenuating 
extramedullary hematopoiesis. 
 
Systemically neutralizing IL-1β lowers blood levels of inflammatory monocytes and neutrophils. 
These myeloid cells drive plaque inflammation, and myeloid cell supply in blood likely influences 
rates of recruitment into the arterial wall and ischemic myocardium. In atherosclerotic plaque, 
CIRCULATIONAHA/2015/016160/R2 
14 
lower leukocyte numbers may lead to smaller lesion size and reduced vulnerability18, 47-49. In the 
MI, reducing blood leukocytosis supports resolution of inflammation and mitigates subsequent 
left ventricular dilation. The ejection fraction was preserved 3 weeks after coronary ligation, 
likely also due to altered macrophage polarization that enhanced myocardial tissue repair50. Our 
observations of IL-1β’s system-wide action correlate well with previous reports on its local 
effects in the infarcted heart35, 36, 42, 46, 51, 52. 
 
Our results have direct clinical relevance, as these experiments used a species-appropriate 
antibody to neutralize IL-1β in mice with MI equivalent to the clinically-approved drug for 
syndromes associated with function gain of the NALP3 inflammasome, which generates active 
IL-1β. The large-scale trial CANTOS is testing whether the FDA-approved anti-human IL-1β 
antibody can limit recurrent events in stable post-MI patients who have residual inflammation, 
despite full standard-of-care treatments, as gauged by a highly sensitive C-reactive protein 
concentration in blood above median41. The data presented here provide novel mechanistic 
insight on this drug's actions. Additionally, our results suggest patients who might have 
recurrent acute MI while receiving anti-IL-1β antibody would not be at greater risk for enhanced 
post-MI heart failure. Indeed, these observations support a trial in acute MI, a proposition tested 
in the MRC trial53 with a much shorter acting IL-1 receptor antagonist that inhibits both the alpha 
and beta isoforms of this multipotent mediator. 
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FIGURE LEGENDS 
Figure 1. IL-1β is released after MI and promotes HSC proliferation.  
(a) Schematic of the experimental set-up. Flow cytometric gating and quantification of 
proliferation rates (BrdU incorporation, bromodeoxyuridine) of bone marrow HSC (hematopoietic 
stem cells) of parabionts in the steady state (upper row), of the non-infarcted wild type (WT) 
parabiont 48h after infarcting the partner (middle row) and of the non-infarcted interleukin-1 
receptor 1 knockout (IL1R1-/-) parabiont 48h after infarcting the partner (lower row). Numbers 
next to gates indicate population frequencies (%) (n = 7-8 per group). (b) Quantification of 
interleukin-1 beta (IL-1β) mRNA and protein levels in the heart, blood and bone marrow (c) in 
the steady state and after acute myocardial infarction (MI) (n = 5 per group). (d) Flow cytometric 
gating and quantification of proliferation rates (cell cycle analysis) of bone marrow HSCs in the 
steady state, 48h after MI and after administration of recombinant mouse IL-1β (rm IL-1β) (n = 5 
per group, mean ± SD, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA). 
 
Figure 2. IL-1β drives HSC proliferation directly. 
(a) Flow cytometric gating for different bone marrow (BM) stromal cell populations (EC, bone 
marrow endothelial cells; MSC, bone marrow mesenchymal stromal cells; OB, bone osteoblastic 
lineage cells). Quantification of interleukin-1 receptor 1 (IL-1R1) expression on hematopoietic 
(HSC and Lin-  sca-1+ c-kit+ cells (LSK)) and stromal (EC, MSC and OB) bone marrow cells by 
qRT-PCR (n = 4-5 per group). (b) Lethally irradiated wild type (WT) mice were reconstituted with 
either wild type or IL1R1-/- bone marrow. Four months later, mice received MI and HSC 
proliferation was quantified 48h later (n = 8-9 per group, mean ± SD, *p<0.05, **p<0.01, 
****p<0.0001, one-way ANOVA). 
 
Figure 3. Neutralizing IL-1β lowers HSC proliferation after MI. 
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(a) Flow cytometric gating and quantification of proliferation rates with BrdU incorporation in 
bone marrow LSK and HSC, 48h after MI. Numbers next to gates indicate population 
frequencies (%) (n = 10-11 per group). (b) Cell cycle analysis in bone marrow LSK and HSC 
48h after MI (n = 5-6 per group). (c) Bone marrow colony forming unit (CFU) assay 48h after MI 
(n = 6 per group). (d) Blood neutrophils and monocytes 7 days after MI (n = 14 per group, mean 
± SD, *p<0.05, Mann-Whitney test). 
 
Figure 4. Neutralizing IL-1β changes the bone marrow microenvironment and dampens 
progenitor release after MI. 
(a) mRNA quantification of HSC retention factors (CXCL12, chemokine (C-X-C motif) ligand 12, 
VCAM-1, vascular cell adhesion molecule 1; SCF, stem cell factor and OPN, osteopontin) in 
flushed bone marrow with qRT-PCR 48h after MI (n = 6 per group, one-way ANOVA). (b) LSK 
numbers in the blood 4d after MI (n = 5-6 per group). (c) Splenic LSK and GMP (granulocyte-
macrophage progenitors), 7d after MI (n = 9-11 per group, mean ± SD, *p<0.05, **p<0.01, 
Mann-Whitney test). 
 
Figure 5. Neutralizing IL-1β attenuates inflammation in infarcted hearts. 
(a) Flow cytometric gating and quantification of neutrophils, macrophages and monocytes in 
infarcted hearts 7d after coronary ligation (n=15 per group). (b) Immunohistochemical 
evaluation of 7d old infarcts for myeloid cells (CD11b) and neutrophils (Ly6G). Bar graphs show 
percentage of positive staining per region of interest (ROI) or number of cells per high power 
field (hpf). Scale bar indicates 50 µm (n = 6 per group, mean ± SD, *p<0.05, **p<0.01, Mann-
Whitney test).  
 
Figure 6. In vivo imaging of anti-IL-1β treatment effects on infarct protease activity and 
post-MI remodeling.  
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(a) Evaluation of post-MI remodeling in ApoE-/- mice by cardiac MRI. Each panel shows the 
short axis of the mid left-ventricular segment at the end of diastole. Infarct size was measured 
as gadolinium enhanced hypokinetic area on day 1 after MI. (b) Imaging infarct protease activity 
7d after MI in ApoE-/- mice by Fluorescence Molecular Tomography-Computed Tomography 
(FMT/CT) (n = 8 per group). (c) End-diastolic volumes (EDV) and left-ventricular ejection 
fraction (LV-EF) were examined serially on day 1 and 21 and are displayed as absolute values 
on day 21 (n = 6 per group, mean ± SD, *p<0.05, Mann-Whitney test). 
 
Figure 7. Neutralizing IL-1β reduces cardiac fibrosis. 
(a) Immunohistochemical evaluation of 7d old infarcts for myofibroblasts (alpha-smooth muscle 
actin, αSMA), collagen deposition (collagen-1) and neovessels (CD31). Bar graphs show 
percentage of positive staining per region of interest (ROI) or number of vessels per high power 
field (hpf). Scale bar indicates 50 µm (n = 6 per group). (b) qRT-PCR of infarct tissue, values 
relative to GAPDH expression with the “MI+Ctrl IgG” group set as 1 (n = 6 per group, mean ± 
SD, *p<0.05, Mann-Whitney test).  
 
Figure 8. Anti-IL-1β treatment reduces leukocyte adhesion molecule expression in 
infarcts and changes macrophage polarization.  
(a) qRT-PCR for leukocyte adhesion molecule expression in infarct tissue 7d after MI, values 
relative to GAPDH expression with the “MI+Ctrl IgG” group set as 1 (n = 6 per group). (b) 
Quantified macrophage polarization markers in FACS-sorted infarct macrophages 4d after 
coronary ligation. qRT-PCR values are relative to GAPDH expression with the “MI+Ctrl IgG” 
group set as 1 (n = 6 per group, mean ± SD, *p<0.05, Mann-Whitney test). 
 
